Hepatitis B Virus (HBV)

CAS No.	Product Name	Inquiry
2469195-67-1	Bifendate-d6 Bifendate-d6 (DDB-d6) is the deuterium labeled Bifendate. Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-HBV efficacy in research of chronic hepatitis B.
2634739-74-3	AB-729 AB-729 is a nucleoside analogue that acts as an RNA interference (RNAi) and can inhibit viral replication, reducing HBV antigens. AB-729 binds to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes entry into hepatocytes through asialoglycoprotein receptor (ASGR).
2712529-19-4	HBV-IN-14 HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection.
2716907-15-0	(5S,8R)-HBV-IN-10 (5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1), which is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). (Extracted from patent WO2021204258A1, compound 6)
2716907-16-1	HBV-IN-10 HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1), which is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). (Extracted from patent WO2021204258A1, compound 6)
2724224-47-7	HBV-IN-6 HBV-IN-6 is a potent inhibitor of HBV with an EC50 of 44 nM. (Extracted from patent WO2021213445A1, compound 3)
2724224-49-9	HBV-IN-7 HBV-IN-7 is a potent inhibitor of HBV with an EC50 of 7 nM. (Extracted from patent WO2021213445A1, compound 5)
2724224-57-9	HBV-IN-8 HBV-IN-8 is a potent inhibitor of HBV with an EC50 of 287.9 nM. (Extracted from patent WO2021213445A1, compound 13)
2724228-72-0	HBV-IN-13 HBV-IN-13 is a potent inhibitor of hepatitis B surface antigen (HBsAg). (Extracted from patent WO2021204252A1, compound 1_B)
2724229-06-3	HBV-IN-12 HBV-IN-12 is a potent inhibitor of hepatitis B surface antigen (HBsAg) (0.001 μM< EC50 ≤0.05 μM). It has anti-HBV DNA activity (0.001 μM
2750254-34-1	HBV-IN-20 HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).
298708-79-9	BAY41-4109 racemic BAY41-4109 racemic, a mixture of R-isomer of BAY41-4109 and S-isomer of BAY41-4109, is an antiviral compound that inhibits HBV replication by destabilizing capsid assembly, with an IC50 of 53 nM.
29984-33-6	ara-Adenosine-5'-monophosphate (ara-AMP) ara-Adenosine-5'-monophosphate (ara-AMP) is an adenosine monophosphate analog with antiviral and possibly antineoplastic properties. It inhibits DNA polymerase and also acts as a chain terminator in DNA replication.
3424-98-4	Telbivudine Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.
40093-94-5	2'-Deoxy-L-cytidine Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment.
40372-00-7	Viramidine Hydrochloride Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
441785-24-6	LB80317 LB80317, an active metabolite of LB80380, inhibits HBV DNA synthesis with an EC50 of 0.5 μM, has antiviral effect and has the potential to treat chronic hepatitis B.
441785-25-7	Besifovir Besifovir is an orally available phosphonate nucleotide for the potential treatment of hepatitis B virus infection was well tolerated and also had a good clinical safety profile.
441785-26-8	Besifovir-Dipivoxil-maleate Besifovir Dipivoxil maleate (LB80380 maleate) is an oral prodrug of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies.
443908-19-8	Glycosmisic Acid Glycosmisic Acid is found in Brucea javanica.

※ Please kindly note that our services are for research use only.